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1. Overview
Genomic sequencing studies indicate that the human gastro-
intestinal (GI) tract is a dynamic repository of about ~1014
micro-organisms that outnumber host cells by at least 100 to
1.1–6 Collectively, these ~1014 microbes contain about 1017
genes; the number of microbial genes is at least 150-fold
greater than the total number of human genes.3,6–10 About 98%
of the microbiota in the human GI tract consists of anaerobic
bacteria, with archaebacteria, fungi, protozoa, prions, viruses of
plant and animal origin, viroids and other micro-organisms, and
other free nucleic acids, such as microRNAs, making up the
remainder. Why evolution selected just 2 of the 54 recognized
major divisions of bacteria Bacteroidetes and Firmicutes to
populate the human GI tract is both enigmatic and open
to speculation—these 2 major phyla represent the “bacterial
core” of our microbiome. The ability of Bacteroidetes and
Furmicutes to coexist symbiotically, to generate essential
vitamins and cofactors, and to process dietary constituents
such as fiber may have made them particularly suitable to
support human immunity, physiology, biochemistry, and
neurochemistry.3,9–12 Of these 2 phyla, the Bacteroidetes, the
largest class of obligate anaerobic gram-negative (G-) bacteria
of the human GI tract, release extraordinarily complex mixtures
of amyloids, lipopolysaccharides (LPSs), enterotoxins, and
neurotoxins. Microbiome-derived exudates appear to be
noxious to multiple aspects of microbiome–host interactions,
including (1) GI tract and blood–brain barrier structure and
integrity; (2) systemic, central nervous system (CNS), and
peripheral nervous system (PNS) homeostasis and equilibrium;
and (3) progressive inflammatory degeneration within the
human nervous system. Interestingly, unique LPS toxins of
the microbiome-abundant Bacteroides fragilis (BF-LPS) and
the B. fragilis toxin (BFT) fragilysin are among the most
barrier-disruptive and proinflammatory neurotoxins known.
This paper overviews some current research and emerging con-
cepts published over the past 6 months on (1) the toxic array of
substances generated by B. fragilis; (2) the potential contribu-
tion of microbiome-generated factors such as BF-LPS in
driving proinflammatory signaling both systemically and
within the nervous system; and (3) the recent recognition of the
beneficial effects of dietary fiber on the growth and prolifera-
tion of B. fragilis and other prolific microbial species in the
human GI tract microbiome, with specific reference to
Alzheimer’s disease (AD) neuropathology wherever possible.
2. BF-LPS amyloids, LPSs, and enterotoxins
A priori, we would like to note that in this paper we are using
as the principal illustration a major anaerobic microbial species
of the GI tract, B. fragilis, as a prime example of an abundant,
G- bacteria of the microbiome; it should be kept in mind that at
least 1000 additional species of GI tract bacteria have both a
dynamic and opportunistic potential to similarly contribute to
(1) the homeostatic maintenance of the GI tract–CNS axis in
health and (2) the development of both systemic and inflam-
matory neurodegenerative disease (Fig. 1). First, B. fragilis
produces 3 major classes of toxic secretory products: amyloid,
LPS, and enterotoxins. They are briefly defined here.
1. Amyloid. The term amyloid is generic for any insoluble,
lipoprotein-enriched molecule exhibiting β-pleated sheet
structures oriented perpendicular to its fibrillar axis; a
remarkably wide variety of microbiome-resident species,
particularly bacteria and fungi, generate significant
quantities of functional amyloids and related microbial
exudates.6–10 Interestingly, well over half of all known
proteins contain “unstructured” regions of amino acids
that are intrinsically amyloidogenic.7–11 For example, the
amyloids that characterizeAD consist largely of “perivas-
cular” amyloid deposits enriched in the 40-amino acid
Aβ40 peptide; “parenchymal” amyloid, enriched in the
42-amino acid Aβ42 peptide; and “nuclear” amyloids,
which contain highly complex mixtures of lipoprotein
fibrils and dense amyloid aggregates.9–12 Interestingly,
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common tertiary protein structures or pathogenic-
associated molecular patterns between microbial and host
amyloids (1) may be involved in propagation or accelera-
tion of amyloidogenesis through “molecular mimicry”
and (2) may be important in the priming of the host innate
immune system and/or microglial cell activation by
microbiota, a factor that may enhance inflammatory and
immunologic responses to AD amyloid.9–16
2. LPS. Distinguishing components of the outer leaflet
of the outer membrane of G- bacteria shed into the
extracellular space, LPSs have historically been thought
to play some host-pathogen immune-evasion strategy
useful to bacterial survival while eliciting strong immune
and proinflammatory responses within the host.8,10,17–20
Although LPSs contain large and hypervariable
polysaccharide/oligosaccharide regions, a relatively con-
served lipid region (known as the “lipid A” core) is the
endotoxic and biologically active moiety that is respon-
sible for the induction of systemic inflammation and
ensuing septic shock.9–12,14–18 Interestingly, it has been
recently shown by several independent groups that
(1) LPS strongly promotes amyloid aggregation,9,10,20
and (2) BF-LPS is one of the most potent inducers of
nuclear factor kappa B (NF-κB) activation in primary
human neuronal-glial cocultures known.17–20
3. Enterotoxins: fragilysin. This is also known as BFT, a
Zn2+-requiring metalloprotease highly cytopathic to intes-
tinal epithelial cells with the following characteristics: (1)
possesses broad proteolytic specificity of hydrolytic
cleavage adjacent to leucines;17–19 (2) hydrolyzes gelatin,
fibrinogen, and extracellular matrix proteins such as the
extracellular domain of type 1 transmembrane proteins
such as E-cadherin;15,19 (3) rapidly degrades intracellular
proteins such as actin and myosin;15,16,20 and (4) disrupts
the tight-junction zona occludens-1 protein of the intes-
tinal epithelial cell.16–21 Taken together, these recent find-
ings indicate that fragilysin’s pathogenic actions (1)
interrupt the integrity of intercellular adhesion;15,18,19 (2)
increase mucosal permeability and the permeability of
the intestinal epithelium to GI tract contents;14–17 and (3)
induce epithelial cell–cell detachment, laying the mor-
phologic basis for a compromised and “leaky” GI tract
barrier.17–23
Clinically, the presence of BF-LPS in the blood serum sig-
nifies (1) a breach of epithelial cell–GI tract barriers; (2) an
early, major, and contributing factor to the initiation and propa-
gation of systemic inflammatory disease; and (3) the first
major biophysical barrier crossed for complex mixtures of
proinflammatory toxins of the GI tract contents to gain access
to the systemic circulation, and onward to the blood–brain
barrier of the CNS. It would be surprising if BF-LPS were not
similarly effective in weakening tight junctions of the blood–
brain barrier, and recent data support this concept.17,19,20 Fur-
thermore, in primary human neuronal-glial cocultures BF-LPS
is (1) an unusually potent inducer of the proinflammatory
transcription factor NF-κB (p50/p65 complex) and hence
proinflammatory gene expression programs and (2) recognized
by toll-like receptors 2 and 4 (TLR2, TLR4) and/or cluster of
differentiation 14 (CD14) microglial cell receptors, as are the
amyloid peptides that characterize AD neuropathology.9,10,20
Fig. 1. Schematic representation of the potential contribution of
gastrointestinal (GI) tract microbiome-derived amyloids, lipopolysaccharides
(LPS), and endotoxins to systemic inflammation and/or to central nervous
system (CNS) neurotoxicity and immune deficits. One of the major microbial
species in the human GI tract is Bacteroides fragilis. In concert with other
microbiome components, this anaerobic gram-negative bacillus generates
complex mixtures of amyloid, LPS, and/or potent neurotoxins such as B. fragilis
toxin (BFT; fragilysin), one of the most potent proinflammatory molecules
known.20–23 Fragilysin is recognized to both (1) increase the paracellular
permeability of the intestinal epithelium largely via the dissolution of tight
junctions in epithelial cells16–19 and (2) at low, physiologically realistic
(nanomolar) concentrations, induce robust inflammatory signaling (such as
activation of nuclear factor kappa B (NF-κB)-DNA binding) in human brain
cells in primary culture20–24 (unpublished observations). The presence of B.
fragilis and/or B. fragilis-derived amyloids, LPSs, or endotoxins such as BFT in
the bloodstream during systemic inflammation (bacteremia) is more common
than any for any other anaerobe of the microbiome.15–23 In combination with
other facultative/obligate anaerobic microbes, their secretory exudates are
extremely powerful proinflammatory and innate immune system activators in
the CNS once they pass GI tract and blood–brain barriers. These actions would
further induce vascular permeability, trigger host immunogenicity, and induce
the generation of reactive oxygen species and NF-κB signaling. For example,
(1) these neuropathogenic signals further promote amyloid aggregation
and inflammatory degeneration characteristic of age-related neurologic
diseases such as AD and other neurologic disorders that exhibit defective
Aβ42 peptide clearance mechanisms and progressive amyloidogenesis,9,24,25
and (2) B. fragilis-derived toxins are also responsible for the majority of
localized abscesses within the cranium.24,25 As a major component of the human
microbiome, GI tract microbial sources of amyloid, LPS, and/or other
microbial-derived endotoxins have a remarkable potential to contribute to
both systemic amyloid and CNS amyloid burden in their respective CNS
compartments. This contribution of noxious, proinflammatory molecules from
the GI tract microbiome may be increasingly important during the course of
aging, when both the GI tract and blood–brain barriers become significantly
more permeable.14–23 Interestingly, high intake of dietary fiber is a strong
inhibitor of B. fragilis abundance and proliferation in the human GI tract
and as such is a potent inhibitor of the neurotoxic B. fragilis-derived
amyloids, LPSs, and enterotoxins. Hence dietary fiber-mediated suppression
of B. fragilis abundance may be beneficial for both human GI tract and CNS
health.14,21–26
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Of related interest is that B. fragilis and its toxins, such as
BF-LPS and fragilysin, also appear to play critical roles in the
postmortem microbiome, when at the point of death the human
microbiome rapidly transforms into the “thanato-microbiome”
(thanatos-, Greek, death) that plays a primary role in the rapid
decomposition of host tissues.9,21
3. Proliferation of BF-LPS in the absence of dietary fiber
The trillions ofmicro-organisms that constitute the humanGI
tract microbiome are reliant on sufficient sources of complex
dietary fibers (sometimes called “roughage”) to promote and
maintain their dynamism and diversity, which support efficient
microbiome–host functions. Indeed, microbiome-accessible
carbohydrates found in dietary fiber provide a critical contribu-
tion to shaping the microbial ecosystem of the GI tract; their
individual distributions are notably altered in high-fat, high-
cholesterol “Western diets” (high in fat and processed carbohy-
drates and low in fiber) compared with more traditional
“Paleolithic diets” (moderate in fat and processed carbohydrates
and high in fiber).16–18 Several recent studies indicate that in
high-fat, high-cholesterol diets deprived of sufficient dietary
fiber, there is an upset in the balance of normal bacterial stoichi-
ometry conducive to human health and a proliferation in B.
fragilis and similar opportunistic anaerobic bacteria.14–20 It is
perhaps not too surprising that diets low in the fiber provided by
complex carbohydrates that favor B. fragilis proliferation are
also associated with increased amyloid, LPS, and endotoxins
such as fragilysin, which are systemically detrimental to health,
supporting leaky barrier functions, which are ultimately
proinflammatory toward the PNS and CNS in a variety of ways.
4. Concluding remarks
The microbiome represents a dynamic ecosystem in which
structure and function are influenced by multiple interactive
factors including age, maternal influences, antibiotic or drug
presence, environment, exercise, metabolism, and stress.
Microbial amyloids, LPSs, and endotoxins of abundant bacte-
rial species such as B. fragilis may be the most obvious
examples of microbiome-resident micro-organisms that can
affect GI tract and blood–brain barrier function, stimulate
proinflammatory signaling systemically, and promote inflam-
matory neurodegeneration of the PNS and CNS. It has been
known for some time that the functional optimization of the
microbiome–GI tract–CNS axis, via studies on GI tract “micro-
bial imbalance” or “dysbiosis” in germ-free animals, the
administration of probiotics, and bacterial infections with
enteric pathogens have strong effects that can ultimately modu-
late cognitive behavior, learning, memory, and healthy brain
aging.22,23 Recent studies underscore the concept that just as
exercise requires the replenishment of efficient and sufficient
energy stores, diets that support optimal CNS and cognitive
health require both a healthy dietary intake and sufficient
dietary fiber to ensure the “best possible performance” of our
microbiome,14–20 leading to the optimization of microbial spe-
ciation and stoichiometry, functional symbiosis, and communi-
cation along the microbiome–GI tract–CNS axis.
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